Table 1.

Clinical characteristics of the primary-metastatic cohort and pathological information associated with the primary ccRCC tumor

	M0 at presentation (N = 57)	M1 (N = 54)	Total (N = 111)
Gender
No	15 (26.3%)	14 (25.9%)	29 (26.1%)
Yes	42 (73.7%)	40 (74.1%)	82 (73.9%)
Age at Surgery (years)
Mean	62.0	58.5	60.3
Median	63.6	59.1	61.4
Range	(34.9–78.8)	(38.2–73.7)	(34.9–78.8)
Max Tumor Size (cm)
Mean	9.6	10.9	10.2
Median	9.0	10.0	9.5
Range	(2.5–18.0)	(2.1–23.0)	(2.1–23.0)
2010 pT
Missing	0	1	1
1A	3 (5.3%)	1 (1.9%)	4 (3.6%)
1B	8 (14.0%)	8 (15.1%)	16 (14.5%)
2A	14 (24.6%)	6 (11.3%)	20 (18.2%)
2B	4 (7.0%)	5 (9.4%)	9 (8.2%)
3A	17 (29.8%)	20 (37.7%)	37 (33.6%)
3B	7 (12.3%)	4 (7.5%)	11 (10.0%)
3C	2 (3.5%)	1 (1.9%)	3 (2.7%)
4	2 (3.5%)	8 (15.1%)	10 (9.1%)
2010 pN
0	18 (31.6%)	20 (37.0%)	38 (34.2%)
1	4 (7.0%)	9 (16.7%)	13 (11.7%)
X	35 (61.4%)	25 (46.3%)	60 (54.1%)
TNM Stage
I	11 (19.3%)	0 (0.0%)	11 (9.9%)
II	18 (31.6%)	0 (0.0%)	18 (16.2%)
III	26 (45.6%)	0 (0.0%)	26 (23.4%)
IV	2 (3.5%)	54 (100.0%)	56 (50.5%)
Grade
1	1 (1.8%)	1 (1.9%)	2 (1.8%)
2	14 (24.6%)	5 (9.3%)	19 (17.1%)
3	32 (56.1%)	31 (57.4%)	63 (56.8%)
4	10 (17.5%)	17 (31.5%)	27 (24.3%)
BAP1 IHC in Primary Tumor
Negative	13 (27.7%)	6 (12.0%)	19 (19.6%)
Positive	34 (72.3%)	44 (88.0%)	78 (80.4%)
NAa			14
PBRM1 IHC in Primary Tumor
Negative	28 (60.9%)	27 (52.9%)	55 (56.7%)
Positive	18 (39.1%)	24 (47.1%)	42 (43.2%)
NAa			14
Number of Longitudinal Metastases
1	34 (59.6%)	41 (75.9%)	75 (67.6%)
2	15 (26.3%)	12 (22.2%)	27 (24.3%)
3	6 (10.5%)	1 (1.9%)	7 (6.3%)
4	2 (3.5%)	0 (0.0%)	2 (1.8%)

^aDenotes that the IHC stain was unsuccessful